Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Letter]

Jeroen JMA Hendrikx,1– 3 Jos H Beijnen,1 Alwin DR Huitema1– 3 1Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; 2Department of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam, The Netherlands; 3Department o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hendrikx JJMA, Beijnen JH, Huitema ADR
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/132b49539ced4d80aaaaca8d3a93adae
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:132b49539ced4d80aaaaca8d3a93adae
record_format	dspace
spelling	oai:doaj.org-article:132b49539ced4d80aaaaca8d3a93adae2021-12-02T11:37:45ZIs Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Letter]1179-1438https://doaj.org/article/132b49539ced4d80aaaaca8d3a93adae2020-10-01T00:00:00Zhttps://www.dovepress.com/is-bodyweight-based-dosing-truly-better-than-flat-dosing-for-panitumum-peer-reviewed-article-CPAAhttps://doaj.org/toc/1179-1438Jeroen JMA Hendrikx,1– 3 Jos H Beijnen,1 Alwin DR Huitema1– 3 1Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; 2Department of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam, The Netherlands; 3Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, The NetherlandsCorrespondence: Jeroen JMA HendrikxDepartment of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1006 BE, The NetherlandsTel +31 205 127 948Email J.Hendrikx@nki.nl With great interest we read the paper by Liao et al in which they compared a 2-weekly bodyweight-based (6 mg/kg) and fixed (480 mg) administration of panitumumab, a monoclonal antibody (Mab) binding the  EGFR receptor.1 The authors used a population pharmacokinetics model to simulate pharmacokinetics of 1200 virtual individuals for each strategy. The observed interpatient variability in mean simulated AUC (CVAUCmean) was compared and was 34% (fixed dosing) versus 29% (bodyweight- based dosing). Based on this, the authors concluded for panitumumab that “body weight-based approach is the recommended patient dosing strategy”.    View the original paper by Liao and colleaguesHendrikx JJMABeijnen JHHuitema ADRDove Medical PressarticleTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol Volume 12, Pp 177-178 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Therapeutics. Pharmacology RM1-950
spellingShingle	Therapeutics. Pharmacology RM1-950 Hendrikx JJMA Beijnen JH Huitema ADR Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Letter]
description	Jeroen JMA Hendrikx,1– 3 Jos H Beijnen,1 Alwin DR Huitema1– 3 1Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; 2Department of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam, The Netherlands; 3Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, The NetherlandsCorrespondence: Jeroen JMA HendrikxDepartment of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1006 BE, The NetherlandsTel +31 205 127 948Email J.Hendrikx@nki.nl With great interest we read the paper by Liao et al in which they compared a 2-weekly bodyweight-based (6 mg/kg) and fixed (480 mg) administration of panitumumab, a monoclonal antibody (Mab) binding the  EGFR receptor.1 The authors used a population pharmacokinetics model to simulate pharmacokinetics of 1200 virtual individuals for each strategy. The observed interpatient variability in mean simulated AUC (CVAUCmean) was compared and was 34% (fixed dosing) versus 29% (bodyweight- based dosing). Based on this, the authors concluded for panitumumab that “body weight-based approach is the recommended patient dosing strategy”.    View the original paper by Liao and colleagues
format	article
author	Hendrikx JJMA Beijnen JH Huitema ADR
author_facet	Hendrikx JJMA Beijnen JH Huitema ADR
author_sort	Hendrikx JJMA
title	Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Letter]
title_short	Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Letter]
title_full	Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Letter]
title_fullStr	Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Letter]
title_full_unstemmed	Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Letter]
title_sort	is bodyweight-based dosing truly better than flat dosing for panitumumab? [letter]
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/132b49539ced4d80aaaaca8d3a93adae
work_keys_str_mv	AT hendrikxjjma isbodyweightbaseddosingtrulybetterthanflatdosingforpanitumumabletter AT beijnenjh isbodyweightbaseddosingtrulybetterthanflatdosingforpanitumumabletter AT huitemaadr isbodyweightbaseddosingtrulybetterthanflatdosingforpanitumumabletter
_version_	1718395745327906816

Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Letter]

Ejemplares similares